ERYTECH announces fast take-off of its Phase IIb study in Acute Myeloid Leukemia Post author:admERY Post published:July 4, 2013 Post category:Newsroom ERYTECH announces a fast take-off of its Phase IIb study in Acute Myeloid Leukemia (AML). You Might Also Like ERYTECH engages in collaborative partnership with EU Horizon 2020 EVIDENCE consortium May 5, 2020 ERYTECH Announces Launch of Investigator-Initiated Phase 2 Study of eryaspase (GRASPA®) for ALL April 4, 2017 ERYTECH to Present at Cowen & Company 39th Annual Healthcare Conference Meeting March 8, 2019
ERYTECH Announces Launch of Investigator-Initiated Phase 2 Study of eryaspase (GRASPA®) for ALL April 4, 2017
